Hypermethylation of the IRAK3-Activated MAPK Signaling Pathway to Promote the Development of Glioma
Authors Wu X, Ouyang Y, Wang B, Lin J, Bai Y
Received 6 March 2020
Accepted for publication 25 June 2020
Published 7 August 2020 Volume 2020:12 Pages 7043—7059
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Eileen O'Reilly
Xinghai Wu,1 Yian Ouyang,2 Bin Wang,1 Jian Lin,1 Yun Bai1
1Department of Neurosurgery, Zhangye People’s Hospital Affiliated to Hexi University, Gansu, People’s Republic of China; 2Department of Neurosurgery, First Affiliated Hospital of Gannan Medical College, Jiangxi, People’s Republic of China
Correspondence: Yun Bai
Department of Neurosurgery, Zhangye People’s Hospital Affiliated to Hexi University, No. 67 Xihuan Road, Ganzhou District, Zhangye City, Gansu Province, People’s Republic of China
Objective: This study aimed to elucidate the molecular mechanism underlying the involvement of abnormal DNA methylation in the development of glioma and identify potential new targets for glioma therapy.
Methods: The GSE79122 chip achieved from the Gene Expression Omnibus (GEO) database containing 69 glioma samples and 9 normal samples was analyzed. Methylation-specific polymerase chain reaction (MS-PCR or MSP), reverse transcription-PCR, and Western blot analysis were used to confirm the methylation level and expression level of the interleukin receptor-associated kinase (IRAK 3) gene in glioma cells, 36 glioma samples, and the corresponding normal samples. In vitro, the proliferation, apoptosis rate, migration, and invasion abilities of glioma cells were detected by Cell Counting Kit-8 assay, Transwell assay, enzyme-linked immunosorbent assay, and flow cytometry, respectively. Besides, the xenograft assay of nude mice was used to confirm the effect of the IRAK3 on glioma in vivo.
Results: Microarray analysis showed that the IRAK3 was one of the most hypermethylated genes in glioma, and the related mitogen-activated protein kinase (MAPK) signaling pathway was activated. More experiments supported the higher methylation level and lower expression level of the IRAK3 in glioma tissues and cell lines. The viability, migration, and invasion ability of glioma cells significantly reduced and the apoptosis rate increased with the overexpression and demethylation of the IRAK3 in vitro. Besides, treatment with the MAPK signaling pathway inhibitor PD325901 alone or the overexpression or demethylation of the IRAK3 had a similar effect as the overexpression or demethylation of the IRAK3 alone in glioma cells. In vivo, xenotransplantation experiments in nude mice confirmed that the overexpression and demethylation of the IRAK3 and suppression of the MAPK signaling pathway inhibited the development of glioma.
Conclusion: IRAK3 inhibited the development of glioma progression through the MAPK signaling pathway.
Keywords: glioma, IRAK3, MAPK signaling pathway, methylation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]